Bromocriptine

Generic name: Pronounced as (broe moe krip' teen)
Brand names
  • Cycloset®
  • Parlodel®
Click on drug name to hear pronunciation

Medical Content Reviewed By HelloPharmacist Staff

Last Revised - 02/15/2022

Bromocriptine (Parlodel) is used to treat symptoms of hyperprolactinemia (high levels of a natural substance called prolactin in the body) including lack of menstrual periods, discharge from the nipples, infertility (difficulty becoming pregnant) and hypogonadism (low levels of certain natural substances needed for normal development and sexual function). Bromocriptine (Parlodel) may be used to treat hyperprolactinemia caused by certain types of tumors that produce prolactin, and may shrink these tumors. Bromocriptine (Parlodel) is also used alone or with other treatments to treat acromegaly (condition in which there is too much growth hormone in the body) and Parkinson's disease (PD; a disorder of the nervous system that causes difficulties with movement, muscle control, and balance). Bromocriptine (Cycloset) is used with a diet and exercise program and sometimes with other medications to control blood sugar levels in people with type 2 diabetes (condition in which the body does not use insulin normally and therefore cannot control the amount of sugar in the blood). Bromocriptine (Cycloset) is not used to treat type 1 diabetes (condition in which the body does not produce insulin and therefore cannot control the amount of sugar in the blood) or diabetic ketoacidosis (a serious condition that may develop if high blood sugar is not treated). Bromocriptine is in a class of medications called dopamine receptor agonists. It treats hyperprolactinemia by decreasing the amount of prolactin in the body. It treats acromegaly by decreasing the amount of growth hormone in the body. It treats Parkinson's disease by stimulating the nerves that control movement. The way bromocriptine works to treat diabetes is not known.

Bromocriptine (Parlodel) comes as a capsule and a tablet to take by mouth. Bromocriptine (Cycloset) comes as a tablet to take by mouth. When bromocriptine (Parlodel) is used to treat hyperprolactinemia, it is usually taken once a day with food. When bromocriptine (Parlodel) is used to treat acromegaly, it is usually taken once a day at bedtime with food. When bromocriptine (Parlodel) is used to treat Parkinson's disease, it is usually taken twice a day with food. Bromocriptine (Cycloset) is usually taken once a day with food within 2 hours of waking in the morning. Take bromocriptine at around the same time(s) every day. Follow the directions on your prescription label carefully, and ask your doctor or pharmacist to explain any part you do not understand. Take bromocriptine exactly as directed. Do not take more or less of it or take it more often than prescribed by your doctor.

Your doctor will probably start you on a low dose of bromocriptine and gradually increase your dose, not more than once every 2 to 28 days. The timing of the dose increases depends on the condition being treated and on your response to the medication.

Bromocriptine may help to control your condition but will not cure it. It may take some time for you to feel the full benefit of bromocriptine. Do not stop taking bromocriptine without talking to your doctor. If you suddenly stop taking bromocriptine, you may experience a lack of interest or concern for usual activities or things you usually care about, anxiety, depression, tiredness, difficulty falling asleep or staying asleep, sweating, or pain. Your doctor will probably decrease your dose gradually.

If you are taking bromocriptine (Cycloset) for diabetes, ask your pharmacist or doctor for a copy of the manufacturer's information for the patient.

Bromocriptine should not be used to stop breast milk production in women who have had an abortion or stillbirth or who have chosen not to breast-feed; bromocriptine may cause serious or fatal adverse effects in these women. Talk with your doctor about the possible risks of using this medication for your condition.

This medication may be prescribed for other uses; ask your doctor or pharmacist for more information.

Before taking bromocriptine,

  • tell your doctor and pharmacist if you are allergic to bromocriptine; ergot alkaloids such as cabergoline (Dostinex), dihydroergotamine (D.H.E. 45, Migranal), ergoloid mesylates (Germinal, Hydergine), ergonovine (Ergotrate), ergotamine (Bellergal-S, Cafergot, Ergomar, Wigraine), methylergonovine (Methergine), methysergide (Sansert), and pergolide (Permax); any other medications; or any of the ingredients in bromocriptine tablets or capsules. Ask your pharmacist for a list of the ingredients.

  • tell your doctor and pharmacist what other prescription and nonprescription medications, vitamins, nutritional supplements, and herbal products you are taking or plan to take. Be sure to mention any of the following: amitriptyline (Elavil); antifungals such as itraconazole (Sporanox) and ketoconazole (Nizoral); antihistamines; chloramphenicol; dexamethasone (Decadron, Dexpak); other dopamine agonists such as cabergoline (Dostinex), levodopa (Dopar, Larodopa), pergolide (Permax), and ropinirole (Requip); ergot-type medications such as dihydroergotamine (D.H.E. 45, Migranal), ergoloid mesylates (Germinal, Hydergine), ergonovine (Ergotrate), ergotamine (Bellergal-S, Cafergot, Ergomar, Wigraine), methylergonovine (Methergine), and methysergide (Sansert); haloperidol (Haldol); imipramine (Tofranil); insulin; macrolide antibiotics such as clarithromycin (Biaxin, in PrevPac) and erythromycin (E.E.S., E-Mycin, Erythrocin); certain medications for human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome (AIDS) such as indinavir (Crixivan), nelfinavir (Viracept), and ritonavir (Norvir, in Kaletra); oral medications for diabetes; medications for asthma, colds, high blood pressure, migraines, and nausea; medications for mental illness such as clozapine (Clozaril, FazaClo), olanzapine (Zyprexa, in Symbyax), thiothixene (Navane), and ziprasidone (Geodon); methyldopa (in Aldoril); metoclopramide (Reglan); nefazodone; octreotide (Sandostatin); pimozide (Orap); probenecid (in Col-Probenecid, Probalan); reserpine; rifampin (Rifadin, in Rifamate, in Rifater, Rimactane); and sumatriptan (Imitrex). Your doctor may need to change the doses of your medications or monitor you carefully for side effects. Many other medications may also interact with bromocriptine, so be sure to tell your doctor about all the medications you are taking, even those that do not appear on this list.

  • tell your doctor if you have high blood pressure or migraine headaches that cause fainting. Your doctor may tell you not to take bromocriptine.

  • tell your doctor if you have recently given birth, if you have ever fainted, and if you have or have ever had a heart attack; a slow, fast, or irregular heartbeat; mental illness; low blood pressure;ulcers; bleeding in the stomach or intestines; Raynaud's syndrome (condition in which the hands and feet become numb and cool when exposed to cold temperatures); heart, kidney, or liver disease; or any condition that prevents you from digesting foods containing sugar, starch, or dairy products normally.

  • tell your doctor if you are pregnant or plan to become pregnant. If you are taking bromocriptine (Parlodel) to treat lack of menstrual periods and infertility caused by hyperprolactinemia, use a method of birth control other than hormonal contraceptives (birth control pills, patches, rings, or injections) until you have regular menstrual periods; then stop using birth control. You should be tested for pregnancy once every 4 weeks as long as you do not menstruate. Once your menstrual period returns, you should be tested for pregnancy any time your menstrual period is 3 days late. If you do not wish to become pregnant, use a method of birth control other than hormonal contraceptives while you are taking bromocriptine. If you become pregnant during your treatment with bromocriptine, stop taking the medication and call your doctor.

  • do not breast-feed while you are taking bromocriptine.

  • if you are having surgery, including dental surgery, tell the doctor or dentist that you are taking bromocriptine (Cycloset).

  • you should know that bromocriptine may make you drowsy and cause you to suddenly fall asleep. Do not drive a car or operate machinery until you know how this medication affects you.

  • ask your doctor about the safe use of alcoholic beverages while you are taking bromocriptine. Alcohol can make the side effects from bromocriptine worse.

  • you should know that some people who used medications such as bromocriptine developed intense urges or behaviors that were compulsive or unusual for them, such as gambling, increased sexual urges or behaviors, and excessive shopping. Call your doctor if you have intense urges to shop, have sex, or gamble, or you are unable to control your behavior. Tell your family members about this risk so that they can call the doctor even if you do not realize that your gambling or any other intense urges or unusual behaviors have become a problem.

  • you should know that bromocriptine may cause dizziness, nausea, sweating, and fainting when you get up too quickly from a lying position. This is more common when you first start taking bromocriptine or when your dose is increased. To avoid this problem, get out of bed slowly, resting your feet on the floor for a few minutes before standing up.

  • ask your doctor what to do if you get sick, develop an infection or fever, experience unusual stress, or are injured. These conditions can affect your blood sugar and the amount of bromocriptine (Cycloset) you may need.

Talk to your doctor about eating grapefruit and drinking grapefruit juice while taking this medicine.

Be sure to follow all exercise and dietary recommendations made by your doctor or dietitian.

If you take bromocriptine (Parlodel), take the missed dose as soon as you remember it. However, if it is almost time for the next dose, skip the missed dose and continue your regular dosing schedule. Do not take a double dose to make up for a missed one.

If you take bromocriptine (Cycloset) once a day and miss your morning dose, wait until the next morning to take your medication. Do not take a double dose to make up for a missed one.

This medication may cause changes in your blood sugar. You should know the symptoms of low and high blood sugar and what to do if you have these symptoms.

  • Bromocriptine may cause side effects. Tell your doctor if any of these symptoms are severe or do not go away:

    • nausea

    • vomiting

    • diarrhea

    • constipation

    • stomach cramps

    • heartburn

    • loss of appetite

    • headache

    • weakness

    • tiredness

    • dizziness or lightheadedness

    • drowsiness

    • difficulty falling asleep or staying asleep

    • depression

  • Some side effects can be serious. If you experience any of these symptoms, call your doctor immediately:

    • fainting

    • watery discharge from the nose

    • numbness, tingling, or pain in your fingers especially in cold weather

    • black and tarry stools

    • bloody vomit

    • vomiting material that looks like coffee grounds

    • swelling of the feet, ankles, or lower legs

    • seizures

    • severe headache

    • blurred or impaired vision

    • slow or difficult speech

    • weakness or numbness of an arm or leg

    • chest pain

    • pain in the arms, back, neck or jaw

    • shortness of breath

    • confusion

    • hallucinations (seeing things or hearing voices that do not exist)

  • Bromocriptine may cause other side effects. Call your doctor if you have any unusual problems while taking this medication.

  • If you experience a serious side effect, you or your doctor may send a report to the Food and Drug Administration's (FDA) MedWatch Adverse Event Reporting program online (http://www.fda.gov/Safety/MedWatch) or by phone (1-800-332-1088).

Keep this medication in the container it came in, tightly closed, and out of reach of children. Store it at room temperature and away from light, excess heat, and moisture (not in the bathroom).

Unneeded medications should be disposed of in special ways to ensure that pets, children, and other people cannot consume them. However, you should not flush this medication down the toilet. Instead, the best way to dispose of your medication is through a medicine take-back program. Talk to your pharmacist or contact your local garbage/recycling department to learn about take-back programs in your community. See the FDA's Safe Disposal of Medicines website (http://goo.gl/c4Rm4p) for more information if you do not have access to a take-back program.

It is important to keep all medication out of sight and reach of children as many containers (such as weekly pill minders and those for eye drops, creams, patches, and inhalers) are not child-resistant and young children can open them easily. To protect young children from poisoning, always lock safety caps and immediately place the medication in a safe location – one that is up and away and out of their sight and reach. http://www.upandaway.org

In case of overdose, call the poison control helpline at 1-800-222-1222. Information is also available online at https://www.poisonhelp.org/help. If the victim has collapsed, had a seizure, has trouble breathing, or can't be awakened, immediately call emergency services at 911.

Symptoms of overdose may include:

  • nausea

  • vomiting

  • constipation

  • sweating

  • pale skin

  • general feeling of discomfort or uneasiness

  • lack of energy

  • fainting

  • dizziness

  • drowsiness

  • confusion

  • hallucinations (seeing things or hearing voices that do not exist)

  • believing things that are not true

  • yawning repeatedly

Keep all appointments with your doctor, eye doctor, and the laboratory. Your blood pressure should be checked periodically. Your doctor may order regular eye examinations and certain lab tests to check your body's response to bromocriptine. Your blood sugar and glycosylated hemoglobin (HbA1c) should be checked regularly to determine your response to bromocriptine (Cycloset). Your doctor will also tell you how to check your response to bromocriptine (Cycloset) by measuring your blood or urine sugar levels at home. Follow these directions carefully.

Do not let anyone else take your medication. Ask your pharmacist any questions you have about refilling your prescription.

It is important for you to keep a written list of all of the prescription and nonprescription (over-the-counter) medicines you are taking, as well as any products such as vitamins, minerals, or other dietary supplements. You should bring this list with you each time you visit a doctor or if you are admitted to a hospital. It is also important information to carry with you in case of emergencies.

  • 2-Br-alpha-ergocryptine
  • 2-Bromoergocryptine
  • Brom-ergocryptine
  • Bromocryptine

Drug Interaction
Moxifloxacin Moxifloxacin The therapeutic efficacy of Bromocriptine can be increased when used in combination with Moxifloxacin.
Repaglinide Repaglinide The risk or severity of hypoglycemia can be increased when Repaglinide is combined with Bromocriptine.
Insulin Glargine (rDNA origin) Injection Insulin Glargine (rDNA origin) Injection The risk or severity of hypoglycemia can be increased when Insulin glargine is combined with Bromocriptine.
Atorvastatin Atorvastatin The metabolism of Atorvastatin can be decreased when combined with Bromocriptine.
Dolasetron Dolasetron The risk or severity of adverse effects can be increased when Dolasetron is combined with Bromocriptine.
Aminophylline Aminophylline The metabolism of Aminophylline can be decreased when combined with Bromocriptine.
Anagrelide Anagrelide The risk or severity of Tachycardia can be increased when Anagrelide is combined with Bromocriptine.
Candesartan Candesartan Bromocriptine may decrease the antihypertensive activities of Candesartan.
Cilostazol Cilostazol The metabolism of Cilostazol can be decreased when combined with Bromocriptine.
Diphenoxylate Diphenoxylate The risk or severity of adverse effects can be increased when Diphenoxylate is combined with Bromocriptine.
Erythromycin and Sulfisoxazole Erythromycin and Sulfisoxazole Erythromycin may increase the vasoconstricting activities of Bromocriptine.
Fenofibrate Fenofibrate The metabolism of Fenofibrate can be decreased when combined with Bromocriptine.
Guanfacine Guanfacine Bromocriptine may increase the hypertensive and vasoconstricting activities of Guanfacine.
Methylergonovine Methylergonovine Methylergometrine may increase the hypertensive and vasoconstricting activities of Bromocriptine.
Miglitol Miglitol The risk or severity of hypoglycemia can be increased when Miglitol is combined with Bromocriptine.
Naratriptan Naratriptan Bromocriptine may increase the vasoconstricting activities of Naratriptan.
Olsalazine Olsalazine Olsalazine may increase the hypoglycemic activities of Bromocriptine.
Paregoric Paregoric The risk or severity of adverse effects can be increased when Morphine is combined with Bromocriptine.
Penbutolol Penbutolol The therapeutic efficacy of Bromocriptine can be increased when used in combination with Acebutolol.
Pentazocine Pentazocine The risk or severity of adverse effects can be increased when Pentazocine is combined with Bromocriptine.
Prednisone Prednisone The risk or severity of hyperglycemia can be increased when Prednisone is combined with Bromocriptine.
Reserpine Reserpine The risk or severity of adverse effects can be increased when Bromocriptine is combined with Reserpine.
Rizatriptan Rizatriptan Bromocriptine may increase the vasoconstricting activities of Rizatriptan.
Sumatriptan Sumatriptan Bromocriptine may increase the vasoconstricting activities of Sumatriptan.
Tacrolimus Tacrolimus The serum concentration of Tacrolimus can be increased when it is combined with Bromocriptine.
Tizanidine Tizanidine The risk or severity of adverse effects can be increased when Tizanidine is combined with Bromocriptine.
Triamcinolone Triamcinolone The risk or severity of hyperglycemia can be increased when Triamcinolone is combined with Bromocriptine.
Zolmitriptan Zolmitriptan Bromocriptine may increase the vasoconstricting activities of Zolmitriptan.
Fluconazole Injection Fluconazole Injection The risk or severity of hypoglycemia can be increased when Bromocriptine is combined with Fluconazole.
Hydromorphone Injection Hydromorphone Injection The risk or severity of adverse effects can be increased when Hydromorphone is combined with Bromocriptine.
Levofloxacin Injection Levofloxacin Injection The therapeutic efficacy of Bromocriptine can be increased when used in combination with Levofloxacin.
Meperidine Injection Meperidine Injection The metabolism of Meperidine can be decreased when combined with Bromocriptine.
Methylprednisolone Injection Methylprednisolone Injection The risk or severity of hyperglycemia can be increased when Methylprednisolone is combined with Bromocriptine.
Metoclopramide Injection Metoclopramide Injection The risk or severity of sedation can be increased when Metoclopramide is combined with Bromocriptine.
Morphine Injection Morphine Injection The risk or severity of adverse effects can be increased when Morphine is combined with Bromocriptine.
Altretamine Altretamine The therapeutic efficacy of Bromocriptine can be decreased when used in combination with Amphetamine.
Cyclosporine Cyclosporine The serum concentration of Cyclosporine can be increased when it is combined with Bromocriptine.
Ondansetron Ondansetron The risk or severity of adverse effects can be increased when Ondansetron is combined with Bromocriptine.
Granisetron Granisetron The risk or severity of adverse effects can be increased when Granisetron is combined with Bromocriptine.
Torsemide Torsemide The therapeutic efficacy of Bromocriptine can be increased when used in combination with Torasemide.
Olanzapine Olanzapine Bromocriptine may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Olanzapine.
Alosetron Alosetron The risk or severity of adverse effects can be increased when Alosetron is combined with Bromocriptine.
Dofetilide Dofetilide The metabolism of Bromocriptine can be decreased when combined with Dofetilide.
Entacapone Entacapone The risk or severity of adverse effects can be increased when Entacapone is combined with Bromocriptine.
Eprosartan Eprosartan Bromocriptine may decrease the antihypertensive activities of Eprosartan.
Hydroxychloroquine Hydroxychloroquine The therapeutic efficacy of Bromocriptine can be increased when used in combination with Hydroxychloroquine.
Meloxicam Meloxicam The risk or severity of hypertension can be increased when Meloxicam is combined with Bromocriptine.
Oxcarbazepine Oxcarbazepine The risk or severity of adverse effects can be increased when Oxcarbazepine is combined with Bromocriptine.
Telmisartan Telmisartan Bromocriptine may decrease the antihypertensive activities of Telmisartan.
Zaleplon Zaleplon The risk or severity of adverse effects can be increased when Zaleplon is combined with Bromocriptine.
Desloratadine Desloratadine The risk or severity of adverse effects can be increased when Desloratadine is combined with Bromocriptine.
Linezolid Linezolid Linezolid may increase the hypertensive activities of Bromocriptine.
Trimipramine Trimipramine Trimipramine may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Bromocriptine.
Glycopyrrolate Glycopyrrolate Bromocriptine may increase the central nervous system depressant (CNS depressant) activities of Glycopyrronium.
Perindopril Perindopril Bromocriptine may decrease the antihypertensive activities of Perindopril.
Tenofovir Tenofovir The metabolism of Tenofovir can be decreased when combined with Bromocriptine.
Choline Magnesium Trisalicylate Choline Magnesium Trisalicylate The risk or severity of hypertension can be increased when Bromocriptine is combined with Choline magnesium trisalicylate.
Sirolimus Sirolimus The metabolism of Sirolimus can be decreased when combined with Bromocriptine.
Dutasteride Dutasteride The risk or severity of hypertension can be increased when Dutasteride is combined with Bromocriptine.
Epinephrine Injection Epinephrine Injection Epinephrine may increase the hypertensive and vasoconstricting activities of Bromocriptine.
Eplerenone Eplerenone Bromocriptine may decrease the antihypertensive activities of Eplerenone.
Escitalopram Escitalopram The risk or severity of adverse effects can be increased when Escitalopram is combined with Bromocriptine.
Olmesartan Olmesartan Bromocriptine may decrease the antihypertensive activities of Olmesartan.
Zonisamide Zonisamide The risk or severity of adverse effects can be increased when Zonisamide is combined with Bromocriptine.
Aripiprazole Aripiprazole Bromocriptine may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Aripiprazole.
Atomoxetine Atomoxetine The risk or severity of adverse effects can be increased when Atomoxetine is combined with Bromocriptine.
Dexmethylphenidate Dexmethylphenidate The risk or severity of adverse effects can be increased when Dexmethylphenidate is combined with Bromocriptine.
Atazanavir Atazanavir The metabolism of Atazanavir can be decreased when combined with Bromocriptine.
Almotriptan Almotriptan Almotriptan may increase the vasoconstricting activities of Bromocriptine.
Eletriptan Eletriptan Eletriptan may increase the vasoconstricting activities of Bromocriptine.
Rosuvastatin Rosuvastatin The therapeutic efficacy of Bromocriptine can be increased when used in combination with Rosuvastatin.
Vardenafil Vardenafil The metabolism of Vardenafil can be decreased when combined with Bromocriptine.
Alfuzosin Alfuzosin The metabolism of Alfuzosin can be decreased when combined with Bromocriptine.
Tadalafil Tadalafil The risk or severity of hypotension, dyspepsia, and headache can be increased when Bromocriptine is combined with Tadalafil.
Fosamprenavir Fosamprenavir The therapeutic efficacy of Bromocriptine can be decreased when used in combination with Fosamprenavir.
Frovatriptan Frovatriptan Bromocriptine may increase the vasoconstricting activities of Frovatriptan.
Gemifloxacin Gemifloxacin The therapeutic efficacy of Bromocriptine can be increased when used in combination with Gemifloxacin.
Progesterone Progesterone The therapeutic efficacy of Bromocriptine can be decreased when used in combination with Progesterone.
Apomorphine Injection Apomorphine Injection The risk or severity of adverse effects can be decreased when Apomorphine is combined with Bromocriptine.
Oxandrolone Oxandrolone Oxandrolone may increase the hypoglycemic activities of Bromocriptine.
Protriptyline Protriptyline Protriptyline may increase the vasopressor activities of Bromocriptine.
Duloxetine Duloxetine The risk or severity of orthostatic hypotension and syncope can be increased when Bromocriptine is combined with Duloxetine.
Norethindrone Norethindrone The therapeutic efficacy of Bromocriptine can be decreased when used in combination with Norethisterone.
Trospium Trospium Bromocriptine may increase the central nervous system depressant (CNS depressant) activities of Trospium.
Bosentan Bosentan The therapeutic efficacy of Bosentan can be increased when used in combination with Bromocriptine.
Erlotinib Erlotinib The metabolism of Erlotinib can be decreased when combined with Bromocriptine.
Eszopiclone Eszopiclone The risk or severity of CNS depression can be increased when Bromocriptine is combined with Eszopiclone.
Insulin Aspart (rDNA Origin) Injection Insulin Aspart (rDNA Origin) Injection The risk or severity of hypoglycemia can be increased when Bromocriptine is combined with Insulin aspart.
Solifenacin Solifenacin Bromocriptine may increase the central nervous system depressant (CNS depressant) activities of Solifenacin.
Dextroamphetamine Dextroamphetamine The therapeutic efficacy of Bromocriptine can be decreased when used in combination with Amphetamine.
Pramlintide Injection Pramlintide Injection The risk or severity of hypoglycemia can be increased when Bromocriptine is combined with Pramlintide.
Sodium Oxybate Sodium Oxybate Sodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Bromocriptine.
Exenatide Injection Exenatide Injection The risk or severity of hypoglycemia can be increased when Bromocriptine is combined with Exenatide.
Isocarboxazid Isocarboxazid Isocarboxazid may increase the hypertensive activities of Bromocriptine.
Ramelteon Ramelteon The risk or severity of adverse effects can be increased when Ramelteon is combined with Bromocriptine.
Darifenacin Darifenacin Bromocriptine may increase the central nervous system depressant (CNS depressant) activities of Darifenacin.
Fentanyl Fentanyl The metabolism of Fentanyl can be decreased when combined with Bromocriptine.
Pregabalin Pregabalin The therapeutic efficacy of Bromocriptine can be increased when used in combination with Pregabalin.
Phenylephrine Phenylephrine Bromocriptine may increase the hypertensive and vasoconstricting activities of Phenylephrine.
Tipranavir Tipranavir The therapeutic efficacy of Bromocriptine can be decreased when used in combination with Tipranavir.
Felbamate Felbamate The risk or severity of adverse effects can be increased when Felbamate is combined with Bromocriptine.
Insulin Detemir (rDNA Origin) Injection Insulin Detemir (rDNA Origin) Injection The risk or severity of hypoglycemia can be increased when Bromocriptine is combined with Insulin detemir.
Rasagiline Rasagiline Rasagiline may increase the hypertensive activities of Bromocriptine.
Sitagliptin Sitagliptin The risk or severity of hypoglycemia can be increased when Sitagliptin is combined with Bromocriptine.
Albuterol Albuterol Salbutamol may increase the hypertensive and vasoconstricting activities of Bromocriptine.
Paliperidone Paliperidone Paliperidone may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Bromocriptine.
Bortezomib Bortezomib The metabolism of Bromocriptine can be decreased when combined with Bortezomib.
Clofarabine Injection Clofarabine Injection The risk or severity of adverse effects can be increased when Clofarabine is combined with Bromocriptine.
Insulin Glulisine (rDNA origin) Injection Insulin Glulisine (rDNA origin) Injection The risk or severity of hypoglycemia can be increased when Bromocriptine is combined with Insulin glulisine.
Posaconazole Posaconazole The serum concentration of Bromocriptine can be increased when it is combined with Posaconazole.
Aliskiren Aliskiren Bromocriptine may decrease the antihypertensive activities of Aliskiren.
Bismuth Subsalicylate Bismuth Subsalicylate Bismuth subsalicylate may increase the hypoglycemic activities of Bromocriptine.
Darunavir Darunavir The therapeutic efficacy of Bromocriptine can be decreased when used in combination with Darunavir.
Dimenhydrinate Dimenhydrinate The risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Bromocriptine.
Lisdexamfetamine Lisdexamfetamine The therapeutic efficacy of Bromocriptine can be decreased when used in combination with Lisdexamfetamine.
Nabilone Nabilone Nabilone may increase the central nervous system depressant (CNS depressant) activities of Bromocriptine.
Retapamulin Retapamulin The metabolism of Retapamulin can be decreased when combined with Bromocriptine.
Vorinostat Vorinostat The therapeutic efficacy of Bromocriptine can be decreased when used in combination with Vorinostat.
Sorafenib Sorafenib The metabolism of Sorafenib can be decreased when combined with Bromocriptine.
Sunitinib Sunitinib The metabolism of Bromocriptine can be decreased when combined with Sunitinib.
Dronabinol Dronabinol Dronabinol may increase the central nervous system depressant (CNS depressant) activities of Bromocriptine.
Levocetirizine Levocetirizine The risk or severity of adverse effects can be increased when Bromocriptine is combined with Levocetirizine.
Dasatinib Dasatinib The metabolism of Dasatinib can be decreased when combined with Bromocriptine.
Temsirolimus Temsirolimus The metabolism of Temsirolimus can be decreased when combined with Bromocriptine.
Nilotinib Nilotinib The metabolism of Bromocriptine can be decreased when combined with Nilotinib.
Budesonide Budesonide The risk or severity of hyperglycemia can be increased when Budesonide is combined with Bromocriptine.
Desmopressin Desmopressin The risk or severity of hypertension can be increased when Desmopressin is combined with Bromocriptine.
OnabotulinumtoxinA Injection OnabotulinumtoxinA Injection The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Bromocriptine.
RimabotulinumtoxinB Injection RimabotulinumtoxinB Injection The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Bromocriptine.
Arsenic Trioxide Injection Arsenic Trioxide Injection The therapeutic efficacy of Bromocriptine can be decreased when used in combination with Arsenic trioxide.
Desvenlafaxine Desvenlafaxine The risk or severity of adverse effects can be increased when Bromocriptine is combined with Desvenlafaxine.
Nebivolol Nebivolol The therapeutic efficacy of Bromocriptine can be increased when used in combination with Nebivolol.
Tretinoin Tretinoin The risk or severity of adverse effects can be increased when Tretinoin is combined with Bromocriptine.
Ixabepilone Injection Ixabepilone Injection The metabolism of Bromocriptine can be decreased when combined with Ixabepilone.
Irinotecan Injection Irinotecan Injection The metabolism of Irinotecan can be decreased when combined with Bromocriptine.
Rufinamide Rufinamide The risk or severity of adverse effects can be increased when Rufinamide is combined with Bromocriptine.
Silodosin Silodosin Silodosin may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Bromocriptine.
Midazolam Midazolam The serum concentration of Midazolam can be increased when it is combined with Bromocriptine.
Milnacipran Milnacipran The risk or severity of adverse effects can be increased when Bromocriptine is combined with Milnacipran.
Fesoterodine Fesoterodine Bromocriptine may increase the central nervous system depressant (CNS depressant) activities of Fesoterodine.
Betaxolol Betaxolol The therapeutic efficacy of Bromocriptine can be increased when used in combination with Betaxolol.
Iloperidone Iloperidone The metabolism of Iloperidone can be decreased when combined with Bromocriptine.
Lacosamide Lacosamide The risk or severity of adverse effects can be increased when Bromocriptine is combined with Lacosamide.
Everolimus Everolimus The metabolism of Everolimus can be decreased when combined with Bromocriptine.
Tolvaptan (low blood sodium) Tolvaptan (low blood sodium) The metabolism of Tolvaptan can be decreased when combined with Bromocriptine.
Dronedarone Dronedarone Bromocriptine may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Dronedarone.
AbobotulinumtoxinA Injection AbobotulinumtoxinA Injection The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Bromocriptine.
Palonosetron Injection Palonosetron Injection The risk or severity of adverse effects can be increased when Palonosetron is combined with Bromocriptine.
Saxagliptin Saxagliptin The risk or severity of hypoglycemia can be increased when Saxagliptin is combined with Bromocriptine.
Romidepsin Injection Romidepsin Injection The metabolism of Romidepsin can be decreased when combined with Bromocriptine.
Tapentadol Tapentadol Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Bromocriptine.
Pazopanib Pazopanib The metabolism of Pazopanib can be decreased when combined with Bromocriptine.
Asenapine Asenapine Asenapine may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Bromocriptine.
Vigabatrin Vigabatrin The risk or severity of adverse effects can be increased when Vigabatrin is combined with Bromocriptine.
Albendazole Albendazole The metabolism of Albendazole can be decreased when combined with Bromocriptine.
Levonorgestrel Levonorgestrel The therapeutic efficacy of Bromocriptine can be decreased when used in combination with Levonorgestrel.
Oxymorphone Oxymorphone The risk or severity of adverse effects can be increased when Oxymorphone is combined with Bromocriptine.
Liraglutide Injection Liraglutide Injection The risk or severity of hypoglycemia can be increased when Bromocriptine is combined with Liraglutide.
IncobotulinumtoxinA Injection IncobotulinumtoxinA Injection The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Bromocriptine.
Cabazitaxel Injection Cabazitaxel Injection The metabolism of Cabazitaxel can be decreased when combined with Bromocriptine.
Lurasidone Lurasidone Bromocriptine may increase the hypotensive activities of Lurasidone.
Vilazodone Vilazodone Bromocriptine may increase the vasoconstricting activities of Vilazodone.
Denileukin Diftitox Injection Denileukin Diftitox Injection The risk or severity of adverse effects can be increased when Aldesleukin is combined with Bromocriptine.
Terbutaline Injection Terbutaline Injection Bromocriptine may increase the hypertensive and vasoconstricting activities of Terbutaline.
Azilsartan Azilsartan The risk or severity of adverse effects can be increased when Bromocriptine is combined with Azilsartan medoxomil.
Busulfan Injection Busulfan Injection The metabolism of Bromocriptine can be decreased when combined with Busulfan.
Roflumilast Roflumilast The metabolism of Roflumilast can be decreased when combined with Bromocriptine.
Linagliptin Linagliptin The metabolism of Linagliptin can be decreased when combined with Bromocriptine.
Cyclophosphamide Injection Cyclophosphamide Injection The metabolism of Cyclophosphamide can be decreased when combined with Bromocriptine.
Triptorelin Injection Triptorelin Injection The therapeutic efficacy of Bromocriptine can be decreased when used in combination with Triptorelin.
Brentuximab Vedotin Injection Brentuximab Vedotin Injection The metabolism of Brentuximab vedotin can be decreased when combined with Bromocriptine.
Ruxolitinib Ruxolitinib The metabolism of Ruxolitinib can be decreased when combined with Bromocriptine.
Vandetanib Vandetanib The metabolism of Vandetanib can be decreased when combined with Bromocriptine.
Clobazam Clobazam The risk or severity of adverse effects can be increased when Clobazam is combined with Bromocriptine.
Vemurafenib Vemurafenib The metabolism of Bromocriptine can be decreased when combined with Vemurafenib.
Axitinib Axitinib The metabolism of Axitinib can be decreased when combined with Bromocriptine.
Crizotinib Crizotinib The metabolism of Crizotinib can be decreased when combined with Bromocriptine.
Cabergoline Cabergoline The risk or severity of adverse effects can be decreased when Cabergoline is combined with Bromocriptine.
Ambrisentan Ambrisentan Bromocriptine may decrease the antihypertensive activities of Ambrisentan.
Ezogabine Ezogabine The risk or severity of adverse effects can be increased when Tiagabine is combined with Bromocriptine.
Iloprost Iloprost The risk or severity of adverse effects can be increased when Iloprost is combined with Bromocriptine.
Mirabegron Mirabegron Mirabegron may increase the hypertensive and vasoconstricting activities of Bromocriptine.
Regorafenib Regorafenib The metabolism of Regorafenib can be decreased when combined with Bromocriptine.
Bosutinib Bosutinib The metabolism of Bosutinib can be decreased when combined with Bromocriptine.
Corticotropin, Repository Injection Corticotropin, Repository Injection The risk or severity of hyperglycemia can be increased when Corticotropin is combined with Bromocriptine.
Lorcaserin Lorcaserin The risk or severity of hypoglycemia can be increased when Bromocriptine is combined with Mecasermin.
Tofacitinib Tofacitinib The metabolism of Tofacitinib can be decreased when combined with Bromocriptine.
Alogliptin Alogliptin The risk or severity of hypoglycemia can be increased when Bromocriptine is combined with Alogliptin.
Ponatinib Ponatinib The metabolism of Ponatinib can be decreased when combined with Bromocriptine.
Pomalidomide Pomalidomide The metabolism of Pomalidomide can be decreased when combined with Bromocriptine.
Ado-trastuzumab Emtansine Injection Ado-trastuzumab Emtansine Injection The metabolism of Trastuzumab emtansine can be decreased when combined with Bromocriptine.
Canagliflozin Canagliflozin Canagliflozin may increase the hypoglycemic activities of Bromocriptine.
Methazolamide Methazolamide The therapeutic efficacy of Bromocriptine can be increased when used in combination with Methazolamide.
Dabrafenib Dabrafenib The metabolism of Bromocriptine can be decreased when combined with Dabrafenib.
Levomilnacipran Levomilnacipran The risk or severity of adverse effects can be increased when Levomilnacipran is combined with Bromocriptine.
Vortioxetine Vortioxetine Bromocriptine may increase the vasoconstricting activities of Vortioxetine.
Perampanel Perampanel Perampanel may increase the central nervous system depressant (CNS depressant) activities of Bromocriptine.
Ibrutinib Ibrutinib The metabolism of Ibrutinib can be decreased when combined with Bromocriptine.
Lomitapide Lomitapide The metabolism of Lomitapide can be decreased when combined with Bromocriptine.
Avanafil Avanafil The risk or severity of hypotension, dyspepsia, and headache can be increased when Avanafil is combined with Bromocriptine.
Ketorolac Injection Ketorolac Injection The risk or severity of hypertension can be increased when Ketorolac is combined with Bromocriptine.
Obinutuzumab Injection Obinutuzumab Injection The risk or severity of adverse effects can be increased when Bromocriptine is combined with Obinutuzumab.
Simeprevir Simeprevir The therapeutic efficacy of Bromocriptine can be increased when used in combination with Simeprevir.
Dapagliflozin Dapagliflozin Dapagliflozin may increase the hypoglycemic activities of Bromocriptine.
Droxidopa Droxidopa Bromocriptine may increase the hypertensive and vasoconstricting activities of Droxidopa.
Ceritinib Ceritinib The metabolism of Ceritinib can be decreased when combined with Bromocriptine.
Albiglutide Injection Albiglutide Injection The risk or severity of hypoglycemia can be increased when Bromocriptine is combined with Albiglutide.
Eslicarbazepine Eslicarbazepine The risk or severity of adverse effects can be increased when Bromocriptine is combined with Eslicarbazepine.
Idelalisib Idelalisib The metabolism of Idelalisib can be decreased when combined with Bromocriptine.
Testosterone Injection Testosterone Injection Testosterone may increase the hypoglycemic activities of Bromocriptine.
Empagliflozin Empagliflozin The risk or severity of hypoglycemia can be increased when Bromocriptine is combined with Empagliflozin.
Vorapaxar Vorapaxar The metabolism of Vorapaxar can be decreased when combined with Bromocriptine.
Hydrocodone Hydrocodone Bromocriptine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.
Suvorexant Suvorexant Bromocriptine may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.
Dulaglutide Injection Dulaglutide Injection The risk or severity of hypoglycemia can be increased when Bromocriptine is combined with Dulaglutide.
Olaparib Olaparib The metabolism of Olaparib can be decreased when combined with Bromocriptine.
Methamphetamine Methamphetamine The therapeutic efficacy of Bromocriptine can be decreased when used in combination with Metamfetamine.
Tasimelteon Tasimelteon The risk or severity of adverse effects can be increased when Bromocriptine is combined with Tasimelteon.
Riociguat Riociguat Bromocriptine may decrease the antihypertensive activities of Riociguat.
Lanreotide Injection Lanreotide Injection The serum concentration of Bromocriptine can be increased when it is combined with Lanreotide.
Nintedanib Nintedanib The metabolism of Nintedanib can be decreased when combined with Bromocriptine.
Risperidone Injection Risperidone Injection Bromocriptine may increase the hypotensive activities of Risperidone.
Palbociclib Palbociclib The metabolism of Palbociclib can be decreased when combined with Bromocriptine.
Insulin Human Inhalation Insulin Human Inhalation The risk or severity of hypoglycemia can be increased when Insulin human is combined with Bromocriptine.
Panobinostat Panobinostat The metabolism of Panobinostat can be decreased when combined with Bromocriptine.
Dinutuximab Injection Dinutuximab Injection The risk or severity of adverse effects can be increased when Bromocriptine is combined with Dinutuximab.
Haloperidol Injection Haloperidol Injection The risk or severity of CNS depression can be increased when Haloperidol is combined with Bromocriptine.
Amiloride Amiloride The risk or severity of adverse effects can be increased when Amiloride is combined with Bromocriptine.
Macitentan Macitentan Bromocriptine may decrease the antihypertensive activities of Macitentan.
Sonidegib Sonidegib The metabolism of Sonidegib can be decreased when combined with Bromocriptine.
Flibanserin Flibanserin Flibanserin may increase the vasoconstricting activities of Bromocriptine.
Prednisolone Prednisolone The risk or severity of hyperglycemia can be increased when Prednisolone is combined with Bromocriptine.
Brexpiprazole Brexpiprazole Bromocriptine may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Brexpiprazole.
Ziprasidone Injection Ziprasidone Injection The risk or severity of adverse effects can be increased when Ziprasidone is combined with Bromocriptine.
Cariprazine Cariprazine Cariprazine may increase the vasoconstricting activities of Bromocriptine.
Insulin Degludec (rDNA Origin) Injection Insulin Degludec (rDNA Origin) Injection The risk or severity of hypoglycemia can be increased when Bromocriptine is combined with Insulin degludec.
Cobimetinib Cobimetinib The metabolism of Cobimetinib can be decreased when combined with Bromocriptine.
Trabectedin Injection Trabectedin Injection The metabolism of Trabectedin can be decreased when combined with Bromocriptine.
Osimertinib Osimertinib The metabolism of Osimertinib can be decreased when combined with Bromocriptine.
Alectinib Alectinib The metabolism of Alectinib can be decreased when combined with Bromocriptine.
Ixazomib Ixazomib The metabolism of Ixazomib can be decreased when combined with Bromocriptine.
Amphotericin B Liposomal Injection Amphotericin B Liposomal Injection The risk or severity of adverse effects can be increased when Amphotericin B is combined with Bromocriptine.
Dexamethasone Injection Dexamethasone Injection The risk or severity of hyperglycemia can be increased when Dexamethasone is combined with Bromocriptine.
Brivaracetam Injection Brivaracetam Injection The risk or severity of adverse effects can be increased when Bromocriptine is combined with Brivaracetam.
Venetoclax Venetoclax The metabolism of Venetoclax can be decreased when combined with Bromocriptine.
Cobicistat Cobicistat The serum concentration of Bromocriptine can be increased when it is combined with Cobicistat.
Midodrine Midodrine Bromocriptine may increase the hypertensive and vasoconstricting activities of Midodrine.
Selexipag Selexipag Bromocriptine may decrease the antihypertensive activities of Selexipag.
Pimavanserin Pimavanserin The therapeutic efficacy of Bromocriptine can be decreased when used in combination with Pimavanserin.
Diphenhydramine Injection Diphenhydramine Injection The risk or severity of adverse effects can be increased when Diphenhydramine is combined with Bromocriptine.
Furosemide Injection Furosemide Injection The therapeutic efficacy of Bromocriptine can be increased when used in combination with Furosemide.
Lixisenatide Injection Lixisenatide Injection The risk or severity of hypoglycemia can be increased when Bromocriptine is combined with Lixisenatide.
Ribociclib Ribociclib The metabolism of Ribociclib can be decreased when combined with Bromocriptine.
Brigatinib Brigatinib The metabolism of Brigatinib can be decreased when combined with Bromocriptine.
Doxepin (Insomnia) Doxepin (Insomnia) Bromocriptine may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Doxepin.
Deflazacort Deflazacort The risk or severity of hyperglycemia can be increased when Deflazacort is combined with Bromocriptine.
Safinamide Safinamide Bromocriptine may increase the hypertensive activities of Safinamide.
Midostaurin Midostaurin The metabolism of Midostaurin can be decreased when combined with Bromocriptine.
Neratinib Neratinib The metabolism of Neratinib can be decreased when combined with Bromocriptine.
Enasidenib Enasidenib The metabolism of Enasidenib can be decreased when combined with Bromocriptine.
Aprepitant/Fosaprepitant Injection Aprepitant/Fosaprepitant Injection The metabolism of Fosaprepitant can be decreased when combined with Bromocriptine.
Copanlisib Injection Copanlisib Injection The metabolism of Copanlisib can be decreased when combined with Bromocriptine.
Delafloxacin Delafloxacin The therapeutic efficacy of Bromocriptine can be increased when used in combination with Delafloxacin.
Abemaciclib Abemaciclib The metabolism of Abemaciclib can be decreased when combined with Bromocriptine.
Acalabrutinib Acalabrutinib The metabolism of Acalabrutinib can be decreased when combined with Bromocriptine.
Semaglutide Injection Semaglutide Injection The risk or severity of hypoglycemia can be increased when Bromocriptine is combined with Semaglutide.
Ertugliflozin Ertugliflozin The therapeutic efficacy of Bromocriptine can be increased when used in combination with Ertugliflozin.
Buprenorphine Injection Buprenorphine Injection Bromocriptine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.
Fostamatinib Fostamatinib The risk or severity of hypotension, dyspepsia, and headache can be increased when Fostamatinib is combined with Bromocriptine.
Baricitinib Baricitinib The metabolism of Baricitinib can be decreased when combined with Bromocriptine.
Lofexidine Lofexidine The therapeutic efficacy of Bromocriptine can be increased when used in combination with Lofexidine.
Eliglustat Eliglustat The metabolism of Eliglustat can be decreased when combined with Bromocriptine.
Ivosidenib Ivosidenib The metabolism of Ivosidenib can be decreased when combined with Bromocriptine.
Cannabidiol Cannabidiol The risk or severity of adverse effects can be increased when Cannabidiol is combined with Bromocriptine.
Dacomitinib Dacomitinib The metabolism of Dacomitinib can be decreased when combined with Bromocriptine.
Duvelisib Duvelisib The metabolism of Duvelisib can be decreased when combined with Bromocriptine.
Stiripentol Stiripentol The risk or severity of adverse effects can be increased when Bromocriptine is combined with Stiripentol.
Gilteritinib Gilteritinib The therapeutic efficacy of Bromocriptine can be decreased when used in combination with Gilteritinib.
Paclitaxel (with albumin) Injection Paclitaxel (with albumin) Injection The metabolism of Paclitaxel can be decreased when combined with Bromocriptine.
Prucalopride Prucalopride The metabolism of Prucalopride can be decreased when combined with Bromocriptine.
Siponimod Siponimod The metabolism of Siponimod can be decreased when combined with Bromocriptine.
Erdafitinib Erdafitinib The metabolism of Erdafitinib can be decreased when combined with Bromocriptine.
Alpelisib Alpelisib The metabolism of Alpelisib can be decreased when combined with Bromocriptine.
Brexanolone Injection Brexanolone Injection The risk or severity of adverse effects can be increased when Bromocriptine is combined with Brexanolone.
Solriamfetol Solriamfetol The risk or severity of hypertension can be increased when Solriamfetol is combined with Bromocriptine.
Entrectinib Entrectinib The metabolism of Entrectinib can be decreased when combined with Bromocriptine.
Pexidartinib Pexidartinib The metabolism of Pexidartinib can be decreased when combined with Bromocriptine.
Pitolisant Pitolisant The serum concentration of Bromocriptine can be decreased when it is combined with Pitolisant.
Lefamulin Lefamulin The metabolism of Lefamulin can be decreased when combined with Bromocriptine.
Phenytoin Injection Phenytoin Injection The risk or severity of adverse effects can be increased when Phenytoin is combined with Bromocriptine.
Fosphenytoin Injection Fosphenytoin Injection The metabolism of Fosphenytoin can be decreased when combined with Bromocriptine.
Zanubrutinib Zanubrutinib The metabolism of Zanubrutinib can be decreased when combined with Bromocriptine.
Voxelotor Voxelotor The serum concentration of Voxelotor can be increased when it is combined with Bromocriptine.
Lumateperone Lumateperone The therapeutic efficacy of Bromocriptine can be decreased when used in combination with Lumateperone.
Lasmiditan Lasmiditan The risk or severity of adverse effects can be increased when Bromocriptine is combined with Lasmiditan.
Tazemetostat Tazemetostat The metabolism of Tazemetostat can be decreased when combined with Bromocriptine.
Cenobamate Cenobamate The serum concentration of Bromocriptine can be decreased when it is combined with Cenobamate.
Teprotumumab-trbw Injection Teprotumumab-trbw Injection The therapeutic efficacy of Bromocriptine can be decreased when used in combination with Teprotumumab.
Tucatinib Tucatinib The metabolism of Tucatinib can be decreased when combined with Bromocriptine.
Selpercatinib Selpercatinib The risk or severity of hypertension can be increased when Bromocriptine is combined with Selpercatinib.
Lemborexant Lemborexant The risk or severity of adverse effects can be increased when Bromocriptine is combined with Lemborexant.
Fenfluramine Fenfluramine The risk or severity of adverse effects can be increased when Fenfluramine is combined with Bromocriptine.
Octreotide Octreotide The risk or severity of adverse effects can be increased when Octreotide is combined with Bromocriptine.
Satralizumab-mwge Injection Satralizumab-mwge Injection The serum concentration of Bromocriptine can be decreased when it is combined with Satralizumab.
Naxitamab-gqgk Injection Naxitamab-gqgk Injection The risk or severity of hypertension can be increased when Bromocriptine is combined with Naxitamab.
Progestin-Only (drospirenone) Oral Contraceptives Progestin-Only (drospirenone) Oral Contraceptives The therapeutic efficacy of Bromocriptine can be decreased when used in combination with Drospirenone.
Viloxazine Viloxazine The risk or severity of adverse effects can be increased when Bromocriptine is combined with Viloxazine.
Theophylline Theophylline The metabolism of Bromocriptine can be decreased when combined with Theophylline.
Fenoprofen Fenoprofen The risk or severity of hypertension can be increased when Fenoprofen is combined with Bromocriptine.
Indomethacin Indomethacin The risk or severity of hypoglycemia can be increased when Indomethacin is combined with Bromocriptine.
Mefenamic Acid Mefenamic Acid The risk or severity of hypertension can be increased when Mefenamic acid is combined with Bromocriptine.
Naproxen Naproxen The risk or severity of hypertension can be increased when Naproxen is combined with Bromocriptine.
Tolmetin Tolmetin The risk or severity of hypertension can be increased when Tolmetin is combined with Bromocriptine.
Sulindac Sulindac The risk or severity of hypertension can be increased when Sulindac is combined with Bromocriptine.
Trazodone Trazodone Trazodone may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Bromocriptine.
Phenobarbital Phenobarbital The risk or severity of adverse effects can be increased when Phenobarbital is combined with Bromocriptine.
Metaxalone Metaxalone The risk or severity of adverse effects can be increased when Metaxalone is combined with Bromocriptine.
Methotrexate Injection Methotrexate Injection The metabolism of Methotrexate can be decreased when combined with Bromocriptine.
Levorphanol Levorphanol The risk or severity of adverse effects can be increased when Levorphanol is combined with Bromocriptine.
Primidone Primidone The risk or severity of adverse effects can be increased when Primidone is combined with Bromocriptine.
Methsuximide Methsuximide The risk or severity of hypotension can be increased when Bromocriptine is combined with Methsuximide.
Diethylpropion Diethylpropion The therapeutic efficacy of Bromocriptine can be decreased when used in combination with Diethylpropion.
Chlorpromazine Chlorpromazine Chlorpromazine may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Bromocriptine.
Diazepam Diazepam The risk or severity of adverse effects can be increased when Diazepam is combined with Bromocriptine.
Oxazepam Oxazepam The risk or severity of adverse effects can be increased when Oxazepam is combined with Bromocriptine.
Flurazepam Flurazepam The risk or severity of adverse effects can be increased when Flurazepam is combined with Bromocriptine.
Clorazepate Clorazepate The risk or severity of adverse effects can be increased when Clorazepic acid is combined with Bromocriptine.
Lorazepam Lorazepam The risk or severity of adverse effects can be increased when Lorazepam is combined with Bromocriptine.
Phenoxybenzamine Phenoxybenzamine Phenoxybenzamine may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Bromocriptine.
Codeine Codeine The risk or severity of adverse effects can be increased when Codeine is combined with Bromocriptine.
Meprobamate Meprobamate The risk or severity of adverse effects can be increased when Meprobamate is combined with Bromocriptine.
Chlordiazepoxide Chlordiazepoxide The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Bromocriptine.
Metaproterenol Metaproterenol Bromocriptine may increase the hypertensive and vasoconstricting activities of Orciprenaline.
Tranylcypromine Tranylcypromine Tranylcypromine may increase the hypertensive activities of Bromocriptine.
Phenelzine Phenelzine Phenelzine may increase the hypertensive activities of Bromocriptine.
Procarbazine Procarbazine Procarbazine may increase the hypertensive activities of Bromocriptine.
Ergoloid Mesylates Ergoloid Mesylates The risk or severity of adverse effects can be decreased when Ergoloid mesylate is combined with Bromocriptine.
Minocycline Minocycline Minocycline may increase the central nervous system depressant (CNS depressant) activities of Bromocriptine.
Prochlorperazine Prochlorperazine The therapeutic efficacy of Bromocriptine can be decreased when used in combination with Prochlorperazine.
Thioridazine Thioridazine Thioridazine may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Bromocriptine.
Trifluoperazine Trifluoperazine Trifluoperazine may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Bromocriptine.
Sulfadiazine Sulfadiazine The risk or severity of hypoglycemia can be increased when Sulfadiazine is combined with Bromocriptine.
Oxycodone Oxycodone The risk or severity of adverse effects can be increased when Oxycodone is combined with Bromocriptine.
Methadone Methadone The risk or severity of adverse effects can be increased when Methadone is combined with Bromocriptine.
Oxybutynin Oxybutynin Bromocriptine may increase the central nervous system depressant (CNS depressant) activities of Oxybutynin.
Benztropine Benztropine Bromocriptine may increase the central nervous system depressant (CNS depressant) activities of Benzatropine.
Maprotiline Maprotiline The risk or severity of adverse effects can be increased when Maprotiline is combined with Bromocriptine.
Ibuprofen Ibuprofen The risk or severity of hypertension can be increased when Ibuprofen is combined with Bromocriptine.
Trihexyphenidyl Trihexyphenidyl Bromocriptine may increase the central nervous system depressant (CNS depressant) activities of Trihexyphenidyl.
Orphenadrine Orphenadrine Bromocriptine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
Perphenazine Perphenazine The therapeutic efficacy of Bromocriptine can be decreased when used in combination with Perphenazine.
Fluphenazine Fluphenazine The therapeutic efficacy of Fluphenazine can be decreased when used in combination with Bromocriptine.
Phentermine Phentermine The therapeutic efficacy of Bromocriptine can be increased when used in combination with Phentermine.
Methylphenidate Methylphenidate The risk or severity of adverse effects can be increased when Methylphenidate is combined with Bromocriptine.
Amoxapine Amoxapine Amoxapine may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Bromocriptine.
Sulfasalazine Sulfasalazine Sulfasalazine may increase the hypoglycemic activities of Bromocriptine.
Hydrocortisone Hydrocortisone The risk or severity of hyperglycemia can be increased when Hydrocortisone is combined with Bromocriptine.
Doxorubicin Doxorubicin The metabolism of Doxorubicin can be decreased when combined with Bromocriptine.
Carbamazepine Carbamazepine The metabolism of Carbamazepine can be decreased when combined with Bromocriptine.
Molindone Molindone The therapeutic efficacy of Molindone can be decreased when used in combination with Bromocriptine.
Methyldopa Methyldopa Bromocriptine may increase the hypertensive and vasoconstricting activities of Methyldopa.
Clonidine Clonidine The risk or severity of sedation can be increased when Clonidine is combined with Bromocriptine.
Prazosin Prazosin Prazosin may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Bromocriptine.
Hydralazine Hydralazine Bromocriptine may decrease the antihypertensive activities of Hydralazine.
Warfarin Warfarin The serum concentration of Warfarin can be increased when it is combined with Bromocriptine.
Clonazepam Clonazepam The risk or severity of adverse effects can be increased when Clonazepam is combined with Bromocriptine.
Loperamide Loperamide The risk or severity of hypotension can be increased when Bromocriptine is combined with Loperamide.
Promethazine Promethazine The risk or severity of adverse effects can be increased when Promethazine is combined with Bromocriptine.
Meclofenamate Meclofenamate The risk or severity of hypertension can be increased when Meclofenamic acid is combined with Bromocriptine.
Loxapine Loxapine The therapeutic efficacy of Loxapine can be decreased when used in combination with Bromocriptine.
Quinine Quinine The risk or severity of adverse effects can be increased when Quinine is combined with Bromocriptine.
Ethosuximide Ethosuximide The risk or severity of adverse effects can be increased when Ethosuximide is combined with Bromocriptine.
Triamterene Triamterene The risk or severity of adverse effects can be increased when Triamterene is combined with Bromocriptine.
Chlorothiazide Chlorothiazide The therapeutic efficacy of Bromocriptine can be decreased when used in combination with Chlorothiazide.
Chlorthalidone Chlorthalidone The therapeutic efficacy of Bromocriptine can be decreased when used in combination with Chlorthalidone.
Metolazone Metolazone The therapeutic efficacy of Bromocriptine can be decreased when used in combination with Metolazone.
Clindamycin Injection Clindamycin Injection The serum concentration of Bromocriptine can be increased when it is combined with Clindamycin.
Secobarbital Secobarbital The risk or severity of adverse effects can be increased when Secobarbital is combined with Bromocriptine.
Desipramine Desipramine Bromocriptine may increase the vasopressor activities of Desipramine.
Amitriptyline Amitriptyline Bromocriptine may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Amitriptyline.
Imipramine Imipramine Bromocriptine may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Imipramine.
Probenecid Probenecid The therapeutic efficacy of Bromocriptine can be increased when used in combination with Probenecid.
Quinidine Quinidine Bromocriptine may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Quinidine.
Disopyramide Disopyramide The risk or severity of hypoglycemia can be increased when Disopyramide is combined with Bromocriptine.
Valproic Acid Valproic Acid The risk or severity of adverse effects can be increased when Valproic acid is combined with Bromocriptine.
Tamoxifen Tamoxifen The metabolism of Tamoxifen can be decreased when combined with Bromocriptine.
Butabarbital Butabarbital The risk or severity of adverse effects can be increased when Butabarbital is combined with Bromocriptine.
Levothyroxine Levothyroxine The therapeutic efficacy of Levothyroxine can be decreased when used in combination with Bromocriptine.
Liothyronine Liothyronine The therapeutic efficacy of Bromocriptine can be decreased when used in combination with Liothyronine.
Chlorpropamide Chlorpropamide The risk or severity of hypoglycemia can be increased when Chlorpropamide is combined with Bromocriptine.
Tolbutamide Tolbutamide The risk or severity of hypoglycemia can be increased when Tolbutamide is combined with Bromocriptine.
Tolazamide Tolazamide The risk or severity of hypoglycemia can be increased when Tolazamide is combined with Bromocriptine.
Dextromethorphan Dextromethorphan The risk or severity of adverse effects can be increased when Dextromethorphan is combined with Bromocriptine.
Cyclobenzaprine Cyclobenzaprine The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Bromocriptine.
Niacin Niacin The therapeutic efficacy of Bromocriptine can be decreased when used in combination with Niacin.
Baclofen Baclofen The therapeutic efficacy of Bromocriptine can be decreased when used in combination with Baclofen.
Doxylamine Doxylamine Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Bromocriptine.
Cyproheptadine Cyproheptadine The risk or severity of adverse effects can be increased when Cyproheptadine is combined with Bromocriptine.
Clemastine Clemastine The risk or severity of adverse effects can be increased when Clemastine is combined with Bromocriptine.
Chlorpheniramine Chlorpheniramine The risk or severity of adverse effects can be increased when Chlorpheniramine is combined with Bromocriptine.
Brompheniramine Brompheniramine The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Bromocriptine.
Meclizine Meclizine The risk or severity of adverse effects can be increased when Meclizine is combined with Bromocriptine.
Methyclothiazide Methyclothiazide The therapeutic efficacy of Bromocriptine can be decreased when used in combination with Methyclothiazide.
Hydrochlorothiazide Hydrochlorothiazide The therapeutic efficacy of Bromocriptine can be decreased when used in combination with Hydrochlorothiazide.
Dantrolene Dantrolene The risk or severity of adverse effects can be increased when Bromocriptine is combined with Dantrolene.
Chlorzoxazone Chlorzoxazone The risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Bromocriptine.
Carisoprodol Carisoprodol The risk or severity of adverse effects can be increased when Carisoprodol is combined with Bromocriptine.
Methocarbamol Methocarbamol The risk or severity of adverse effects can be increased when Methocarbamol is combined with Bromocriptine.
Danazol Danazol The therapeutic efficacy of Bromocriptine can be decreased when used in combination with Danazol.
Propranolol (Cardiovascular) Propranolol (Cardiovascular) The therapeutic efficacy of Bromocriptine can be increased when used in combination with Propranolol.
Minoxidil Minoxidil Bromocriptine may decrease the antihypertensive activities of Minoxidil.
Pseudoephedrine Pseudoephedrine The therapeutic efficacy of Pseudoephedrine can be decreased when used in combination with Bromocriptine.
Nortriptyline Nortriptyline Bromocriptine may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Nortriptyline.
Spironolactone Spironolactone The therapeutic efficacy of Bromocriptine can be decreased when used in combination with Spironolactone.
Amphotericin B Injection Amphotericin B Injection The risk or severity of adverse effects can be increased when Amphotericin B is combined with Bromocriptine.
Nadolol Nadolol The therapeutic efficacy of Bromocriptine can be increased when used in combination with Nadolol.
Butorphanol Injection Butorphanol Injection The risk or severity of adverse effects can be increased when Butorphanol is combined with Bromocriptine.
Nalbuphine Injection Nalbuphine Injection The risk or severity of adverse effects can be increased when Nalbuphine is combined with Bromocriptine.
Fluoxymesterone Fluoxymesterone Fluoxymesterone may increase the hypoglycemic activities of Bromocriptine.
Trimethobenzamide Trimethobenzamide The risk or severity of adverse effects can be increased when Trimethobenzamide is combined with Bromocriptine.
Flavoxate Flavoxate Bromocriptine may increase the central nervous system depressant (CNS depressant) activities of Flavoxate.
Papaverine Papaverine The risk or severity of adverse effects can be increased when Papaverine is combined with Bromocriptine.
Colchicine Colchicine The metabolism of Colchicine can be decreased when combined with Bromocriptine.
Cephalexin Cephalexin The metabolism of Cephalexin can be decreased when combined with Bromocriptine.
Acetazolamide Acetazolamide The risk or severity of adverse effects can be increased when Acetazolamide is combined with Bromocriptine.
Pyrantel Pyrantel The risk or severity of adverse effects can be increased when Bromocriptine is combined with Pyrantel.
Thiotepa Injection Thiotepa Injection The metabolism of Thiotepa can be decreased when combined with Bromocriptine.
Vincristine Injection Vincristine Injection The metabolism of Vincristine can be decreased when combined with Bromocriptine.
Captopril Captopril Bromocriptine may decrease the antihypertensive activities of Captopril.
Dipyridamole Dipyridamole The risk or severity of hypotension, dyspepsia, and headache can be increased when Dipyridamole is combined with Bromocriptine.
Isoxsuprine Isoxsuprine Bromocriptine may increase the hypertensive and vasoconstricting activities of Isoxsuprine.
Vinblastine Vinblastine The metabolism of Vinblastine can be decreased when combined with Bromocriptine.
Ethacrynic Acid Ethacrynic Acid The therapeutic efficacy of Bromocriptine can be decreased when used in combination with Etacrynic acid.
Metoprolol Metoprolol The therapeutic efficacy of Bromocriptine can be increased when used in combination with Metoprolol.
Hydroxyzine Hydroxyzine Hydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Bromocriptine.
Thiothixene Thiothixene The therapeutic efficacy of Thiothixene can be decreased when used in combination with Bromocriptine.
Aspirin Aspirin The risk or severity of hypoglycemia can be increased when Acetylsalicylic acid is combined with Bromocriptine.
Salsalate Salsalate The risk or severity of hypertension can be increased when Bromocriptine is combined with Salsalate.
Alprazolam Alprazolam The metabolism of Alprazolam can be decreased when combined with Bromocriptine.
Temazepam Temazepam The risk or severity of adverse effects can be increased when Temazepam is combined with Bromocriptine.
Triazolam Triazolam The risk or severity of adverse effects can be increased when Triazolam is combined with Bromocriptine.
Dicyclomine Dicyclomine Bromocriptine may increase the central nervous system depressant (CNS depressant) activities of Dicyclomine.
Hyoscyamine Hyoscyamine Bromocriptine may increase the central nervous system depressant (CNS depressant) activities of Hyoscyamine.
Propantheline Propantheline Bromocriptine may increase the central nervous system depressant (CNS depressant) activities of Propantheline.
Diltiazem Diltiazem The risk or severity of hypotension can be increased when Bromocriptine is combined with Diltiazem.
Nifedipine Nifedipine The risk or severity of hypotension can be increased when Bromocriptine is combined with Nifedipine.
Timolol Timolol The therapeutic efficacy of Bromocriptine can be increased when used in combination with Timolol.
Verapamil Verapamil Verapamil may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Bromocriptine.
Atenolol Atenolol The therapeutic efficacy of Bromocriptine can be increased when used in combination with Atenolol.
Pindolol Pindolol The therapeutic efficacy of Bromocriptine can be increased when used in combination with Pindolol.
Diflunisal Diflunisal Diflunisal may increase the hypoglycemic activities of Bromocriptine.
Piroxicam Piroxicam The risk or severity of hypertension can be increased when Piroxicam is combined with Bromocriptine.
Bumetanide Bumetanide The therapeutic efficacy of Bromocriptine can be increased when used in combination with Bumetanide.
Etoposide Etoposide The metabolism of Etoposide can be decreased when combined with Bromocriptine.
Glyburide Glyburide The risk or severity of hypoglycemia can be increased when Glyburide is combined with Bromocriptine.
Glipizide Glipizide The risk or severity of hypoglycemia can be increased when Glipizide is combined with Bromocriptine.
Indapamide Indapamide The therapeutic efficacy of Indapamide can be decreased when used in combination with Bromocriptine.
Pentoxifylline Pentoxifylline The risk or severity of hypotension, dyspepsia, and headache can be increased when Pentoxifylline is combined with Bromocriptine.
Pentamidine Injection Pentamidine Injection The therapeutic efficacy of Bromocriptine can be decreased when used in combination with Pentamidine.
Labetalol Labetalol Labetalol may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Bromocriptine.
Leuprolide Injection Leuprolide Injection The therapeutic efficacy of Bromocriptine can be decreased when used in combination with Leuprolide.
Guanabenz Guanabenz Bromocriptine may increase the hypertensive and vasoconstricting activities of Guanabenz.
Ketoprofen Ketoprofen The risk or severity of hypertension can be increased when Ketoprofen is combined with Bromocriptine.
Pimozide Pimozide The therapeutic efficacy of Bromocriptine can be decreased when used in combination with Pimozide.
Enalapril Enalapril Bromocriptine may decrease the antihypertensive activities of Enalapril.
Flurbiprofen Flurbiprofen The risk or severity of hypertension can be increased when Flurbiprofen is combined with Bromocriptine.
Amiodarone Amiodarone The metabolism of Bromocriptine can be decreased when combined with Amiodarone.
Buspirone Buspirone The therapeutic efficacy of Bromocriptine can be decreased when used in combination with Buspirone.
Lovastatin Lovastatin The metabolism of Lovastatin can be decreased when combined with Bromocriptine.
Ciprofloxacin Ciprofloxacin The therapeutic efficacy of Bromocriptine can be increased when used in combination with Ciprofloxacin.
Mesalamine Mesalamine Mesalazine may increase the hypoglycemic activities of Bromocriptine.
Diclofenac Diclofenac The risk or severity of hypertension can be increased when Diclofenac is combined with Bromocriptine.
Fluoxetine Fluoxetine Fluoxetine may increase the central nervous system depressant (CNS depressant) activities of Bromocriptine.
Nimodipine Nimodipine The risk or severity of hypoglycemia can be increased when Nimodipine is combined with Bromocriptine.
Clozapine Clozapine Bromocriptine may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Clozapine.
Estazolam Estazolam The risk or severity of adverse effects can be increased when Bromocriptine is combined with Estazolam.
Ofloxacin Ofloxacin The therapeutic efficacy of Bromocriptine can be increased when used in combination with Ofloxacin.
Clarithromycin Clarithromycin The serum concentration of Bromocriptine can be increased when it is combined with Clarithromycin.
Benazepril Benazepril The risk or severity of hypoglycemia can be increased when Benazepril is combined with Bromocriptine.
Etodolac Etodolac The risk or severity of hypertension can be increased when Etodolac is combined with Bromocriptine.
Felodipine Felodipine The risk or severity of hypotension can be increased when Bromocriptine is combined with Felodipine.
Fosinopril Fosinopril Bromocriptine may decrease the antihypertensive activities of Fosinopril.
Nabumetone Nabumetone The risk or severity of hypertension can be increased when Nabumetone is combined with Bromocriptine.
Quinapril Quinapril Bromocriptine may decrease the antihypertensive activities of Quinapril.
Ramipril Ramipril Bromocriptine may decrease the antihypertensive activities of Ramipril.
Amlodipine Amlodipine The risk or severity of hypoglycemia can be increased when Amlodipine is combined with Bromocriptine.
Teniposide Injection Teniposide Injection The metabolism of Teniposide can be decreased when combined with Bromocriptine.
Lisinopril Lisinopril Bromocriptine may decrease the antihypertensive activities of Lisinopril.
Oxaprozin Oxaprozin The risk or severity of hypertension can be increased when Oxaprozin is combined with Bromocriptine.
Sotalol Sotalol The risk or severity of hypoglycemia can be increased when Sotalol is combined with Bromocriptine.
Bisoprolol Bisoprolol The therapeutic efficacy of Bromocriptine can be increased when used in combination with Bisoprolol.
Zolpidem Zolpidem Bromocriptine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.
Doxazosin Doxazosin Doxazosin may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Bromocriptine.
Terazosin Terazosin Terazosin may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Bromocriptine.
Isradipine Isradipine The risk or severity of hypotension can be increased when Bromocriptine is combined with Isradipine.
Cisapride Cisapride The risk or severity of adverse effects can be increased when Cisapride is combined with Bromocriptine.
Gabapentin Gabapentin The risk or severity of adverse effects can be increased when Gabapentin is combined with Bromocriptine.
Venlafaxine Venlafaxine The risk or severity of adverse effects can be increased when Venlafaxine is combined with Bromocriptine.
Famciclovir Famciclovir The metabolism of Famciclovir can be decreased when combined with Bromocriptine.
Fluvoxamine Fluvoxamine The risk or severity of adverse effects can be increased when Bromocriptine is combined with Fluvoxamine.
Nefazodone Nefazodone Bromocriptine may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Nefazodone.
Lamotrigine Lamotrigine The risk or severity of hypotension can be increased when Bromocriptine is combined with Lamotrigine.
Losartan Losartan Bromocriptine may decrease the antihypertensive activities of Losartan.
Tramadol Tramadol The metabolism of Bromocriptine can be decreased when combined with Tramadol.
Vinorelbine Injection Vinorelbine Injection The metabolism of Vinorelbine can be decreased when combined with Bromocriptine.
Moexipril Moexipril Bromocriptine may decrease the antihypertensive activities of Moexipril.
Ifosfamide Injection Ifosfamide Injection The metabolism of Ifosfamide can be decreased when combined with Bromocriptine.
Nicardipine Nicardipine Bromocriptine may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Nicardipine.
Bupropion Bupropion The risk or severity of adverse effects can be increased when Bupropion is combined with Bromocriptine.
Ticlopidine Ticlopidine The metabolism of Ticlopidine can be decreased when combined with Bromocriptine.
Saquinavir Saquinavir The therapeutic efficacy of Bromocriptine can be decreased when used in combination with Saquinavir.
Metformin Metformin The risk or severity of hypoglycemia can be increased when Metformin is combined with Bromocriptine.
Nisoldipine Nisoldipine The risk or severity of hypotension can be increased when Bromocriptine is combined with Nisoldipine.
Riluzole Riluzole The risk or severity of adverse effects can be increased when Riluzole is combined with Bromocriptine.
Amifostine Injection Amifostine Injection The risk or severity of adverse effects can be increased when Amifostine is combined with Bromocriptine.
Acarbose Acarbose The risk or severity of hypoglycemia can be increased when Acarbose is combined with Bromocriptine.
Glimepiride Glimepiride The risk or severity of hypoglycemia can be increased when Glimepiride is combined with Bromocriptine.
Indinavir Indinavir The therapeutic efficacy of Bromocriptine can be decreased when used in combination with Indinavir.
Ritonavir Ritonavir The serum concentration of Bromocriptine can be increased when it is combined with Ritonavir.
Docetaxel Injection Docetaxel Injection The metabolism of Docetaxel can be decreased when combined with Bromocriptine.
Clomipramine Clomipramine The metabolism of Clomipramine can be decreased when combined with Bromocriptine.
Zafirlukast Zafirlukast The metabolism of Zafirlukast can be decreased when combined with Bromocriptine.
Mirtazapine Mirtazapine Mirtazapine may decrease the antihypertensive activities of Bromocriptine.
Trandolapril Trandolapril Bromocriptine may decrease the antihypertensive activities of Trandolapril.
Topiramate Topiramate The risk or severity of adverse effects can be increased when Topiramate is combined with Bromocriptine.
Valsartan Valsartan Bromocriptine may decrease the antihypertensive activities of Valsartan.
Insulin Lispro Injection Insulin Lispro Injection The risk or severity of hypoglycemia can be increased when Insulin lispro is combined with Bromocriptine.
Pramipexole Pramipexole Pramipexole may increase the sedative activities of Bromocriptine.
Donepezil Donepezil The risk or severity of adverse effects can be increased when Donepezil is combined with Bromocriptine.
Nelfinavir Nelfinavir The therapeutic efficacy of Bromocriptine can be decreased when used in combination with Nelfinavir.
Azithromycin Azithromycin The serum concentration of Bromocriptine can be increased when it is combined with Azithromycin.
Carvedilol Carvedilol Carvedilol may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Bromocriptine.
Selegiline Selegiline Selegiline may increase the hypertensive activities of Bromocriptine.
Bicalutamide Bicalutamide The metabolism of Bicalutamide can be decreased when combined with Bromocriptine.
Sertraline Sertraline The risk or severity of adverse effects can be increased when Bromocriptine is combined with Sertraline.
Propafenone Propafenone The therapeutic efficacy of Bromocriptine can be increased when used in combination with Propafenone.
Irbesartan Irbesartan Bromocriptine may decrease the antihypertensive activities of Irbesartan.
Tamsulosin Tamsulosin Tamsulosin may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Bromocriptine.
Ropinirole Ropinirole Ropinirole may increase the sedative activities of Bromocriptine.
Finasteride Finasteride The risk or severity of hypertension can be increased when Bromocriptine is combined with Finasteride.
Quetiapine Quetiapine Bromocriptine may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Quetiapine.
Cetirizine Cetirizine The risk or severity of adverse effects can be increased when Cetirizine is combined with Bromocriptine.
Paroxetine Paroxetine The risk or severity of adverse effects can be increased when Bromocriptine is combined with Paroxetine.
Tolcapone Tolcapone The risk or severity of adverse effects can be increased when Tolcapone is combined with Bromocriptine.
Citalopram Citalopram The risk or severity of adverse effects can be increased when Bromocriptine is combined with Citalopram.
Efavirenz Efavirenz The risk or severity of adverse effects can be increased when Efavirenz is combined with Bromocriptine.
Sildenafil Sildenafil The risk or severity of hypotension, dyspepsia, and headache can be increased when Sildenafil is combined with Bromocriptine.
Pioglitazone Pioglitazone The risk or severity of hypoglycemia can be increased when Pioglitazone is combined with Bromocriptine.
Celecoxib Celecoxib The therapeutic efficacy of Bromocriptine can be increased when used in combination with Celecoxib.
Rosiglitazone Rosiglitazone The risk or severity of hypoglycemia can be increased when Rosiglitazone is combined with Bromocriptine.
Tolterodine Tolterodine Bromocriptine may increase the central nervous system depressant (CNS depressant) activities of Tolterodine.
Thalidomide Thalidomide Bromocriptine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
Balsalazide Balsalazide Balsalazide may increase the hypoglycemic activities of Bromocriptine.
Nateglinide Nateglinide The risk or severity of hypoglycemia can be increased when Nateglinide is combined with Bromocriptine.
Levetiracetam Levetiracetam The risk or severity of adverse effects can be increased when Bromocriptine is combined with Levetiracetam.

Content provided by: AHFS® Patient Medication Information™. © Copyright, 2021. The American Society of Health-System Pharmacists